01—Abstract
Summary
Summary of the 10-K filed February 12, 2021. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' FY2020 10-K shows a year of strong recovery and growth despite the COVID-19 disruption to veterinary visits in the first half.
Total revenue rose 12.5% reported (12.0% organic) to $2.71 billiona, and Companion Animal Group (CAG) revenue grew 12.6% to $2.39 billion, with recurring diagnostic revenue (about 78% of consolidated revenue) up 15.6%. Gross margin expanded 130 basis points to 58.0%, and operating income rose 25.6% to $694.5 million, or 25.7% of revenue. Diluted EPS reached $6.71, up from $4.89, aided in part by a one-time Swiss tax reform benefit that lowered the effective tax rate to 12.1%.
Operating cash flow was $648.1 millionb, and the company ended the year with $383.9 million in cash and no borrowings under its $1 billion revolving credit facility. The balance sheet strengthened notably. Stockholders' equity rose to $632.8 million from $177.8 million, reflecting net income and stock issuance, and gross debt of $910.7 million implies a net debt to Adjusted EBITDA ratio of 0.64x, well within the 3.5x covenant.
The company issued $200 millionc of 2.50% senior notes in April 2020, repurchased roughly $180 million of stock, and resumed buybacks in early 2021 after suspending them in the first quarter of 2020. The 2021 capital expenditure plan is $120 million to $140 million.
Key risks include the durability of pandemic-driven demand in companion animal care, an unresolved royalty litigation with a $50 milliond claim against which the company holds a $27.5 million accrual, growing consolidation among veterinary hospital owners and buying groups, foreign currency headwinds (38% of revenue is international), and the expiration of a Netherlands tax ruling at the end of 2022. The COVID-19 PCR testing sales in the Other segment are described as difficult to forecast and may not persist.
02—Key points
Key Highlights
- Total revenue grew 12.5% reported (12.0% organic) to $2,706.7 million, with CAG contributing $2,385.8 million, up 12.6%.
- Recurring CAG diagnostic revenue reached $2,113.8 million, up 15.6%, and represented about 78% of consolidated revenue, supported by IDEXX VetLab consumables (+18.9%) and reference laboratory services (+15.0%).
- Operating income increased 25.6% to $694.5 million, with operating margin expanding to 25.7% from 23.0%; gross margin rose 130 basis points to 58.0%.
- Diluted EPS was $6.71, up from $4.89 in 2019, helped by a one-time Swiss tax reform benefit that reduced the effective tax rate to 12.1% (18.1% in 2019).
- Operating cash flow rose to $648.1 million, and cash ended the year at $383.9 million with no outstanding borrowings under the $1 billion Credit Facility.
- Net debt to Adjusted EBITDA was 0.64x, and the company was in compliance with its 3.5x leverage covenant; buybacks were suspended in Q1 2020 and resumed in Q1 2021.
- Material risks include a $50 million royalty underpayment claim (with a $27.5 million accrual), ongoing consolidation of veterinary hospitals, and a Netherlands tax ruling expiring December 31, 2022.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, IDEXX Laboratories kept $0.22.
- Revenue$2.71B100.0%
- Cost of revenue−$1.14B42.0%
- Gross profit$1.57B58.0%
- Operating costs−$876.5M32.4%
- Operating income$694.5M25.7%
- Interest, other & tax−$112.4M4.2%
- Net income$582.1M21.5%
Where FY2020 revenue went
$2.71B- Cost of revenue: $1.14B, 42% of revenue
- Other operating costs: $735.3M, 27% of revenue
- Net income: $582.1M, 22% of revenue
- R&D: $141.2M, 5.2% of revenue
- Interest, other & tax: $112.4M, 4.2% of revenue
Kept 22% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 12, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $2.71B$2.41B | +12.5% |
| Cost of Revenue | $1.14B$1.04B | +9.1% |
| Gross Profit | $1.57B$1.37B | +15.0% |
| R&D Expenses | $141.25M$133.19M | +6.0% |
| Operating Income | $694.52M$552.85M | +25.6% |
| Interest Expense | $33.13M$31.05M | +6.7% |
| Net Income | $582.13M$427.79M | +36.1% |
| EPS (Basic) | $6.82$4.97 | +37.2% |
| EPS (Diluted) | $6.71$4.89 | +37.2% |
| Shares Outstanding (Basic) | 85.34M86.11M | −0.9% |
| Shares Outstanding (Diluted) | 86.72M87.54M | −0.9% |
05—Questions
Frequently Asked Questions
What drove IDEXX's revenue growth in 2020 despite the COVID-19 pandemic?
After a sharp decline in late March through mid-April 2020 when stay-at-home orders limited veterinary visits, companion animal demand rebounded strongly from June onward. Growth was supported by pent-up demand for wellness and non-wellness testing, higher clinical visits from new patients, and an increase in pet ownership. Higher volumes of IDEXX VetLab consumables and reference laboratory testing drove most of the CAG recurring revenue increase, while new CAG instrument placements fell 17.9% due to restricted sales-rep access to clinics.
How strong is IDEXX's balance sheet and liquidity position?
The company ended 2020 with $383.9 million in cash and no borrowings under its $1 billion revolving credit facility, which had $998.6 million of availability and was extended to April 2023. Working capital was $480.0 million, versus negative $45.7 million a year earlier. Total debt was $909.1 million, including $200 million of new 2.50% senior notes issued in 2020. Management said current resources are sufficient for at least the next twelve months.
Is the 2020 earnings improvement sustainable, given the one-time tax benefit?
Not entirely. The effective tax rate fell to 12.1% from 18.1%, largely because of a one-time benefit from Swiss tax reform, a deferred tax asset recorded on transitional benefits, and larger share-based compensation tax benefits. Operating income growth of 25.6% is a better gauge of the underlying business, though it also benefited from pandemic-era cost containment such as lower travel and temporary compensation reductions. The company also flagged that the Netherlands tax ruling expires at the end of 2022 and will not be renewed, creating future tax rate uncertainty.
What are the most significant risks to IDEXX's future results?
Key risks include whether the surge in companion animal demand and the COVID-19 PCR testing revenue in the Other segment will persist, since management called that demand difficult to forecast. Consolidation among corporate hospital owners and buying consortiums could pressure pricing and shift testing to competing reference labs. About 38% of revenue is international and exposed to a stronger US dollar, which management estimated would reduce 2021 revenue by about $11 million per 1% of dollar strength. The company also faces a $50 million royalty claim, with a $27.5 million accrual, that it is appealing after an adverse trial ruling.
How is IDEXX returning capital to shareholders?
IDEXX has never paid a cash dividend and has no current plans to do so. Instead, it returns capital through share repurchases under a program with about 6.3 million shares remaining. The company repurchased about 0.7 million shares for $179.6 million in 2020, down from $303.8 million in 2019, after suspending open-market buybacks in early 2020 due to pandemic uncertainty. It resumed repurchases in the first quarter of 2021.
06—Continue